ALAUNOS THERAPEUTICS INC (TCRT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$1.56-0.64%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Warn: Primary pillar under pressure — Maintain Nasdaq listing compliance: Nasdaq Rule 5550(b)(1) equity <$2.5M vs $2.5M.
Alaunos aims to maintain Nasdaq listing compliance and resolve disputes with MD Anderson. The company has a market cap of $5M and is working on strategic partnerships. Management progress scores are 40% on key priorities, showing some advancement.
The company is loss-making with a negative free cash flow yield of -0.91 and a 33.7% drawdown from its high. Analysts expect revenue to decline by about 60% next year. Nasdaq delisting risk remains a major threat.
The market expects about -60% revenue growth next year and a severe decline in business. Our fair value is $0.26, but the stock price has fallen 33.7% from its high, reflecting high risk. We see the market pricing in a difficult turnaround with uncertain recovery.
Breaks if: Disputes remain unresolved beyond next 4 quarters
Settle outstanding disputes with MD Anderson Cancer Center related to unpaid invoices.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity, as TCRT is focused on early-stage development in the healthcare sector. The current thesis state indicates a cautious approach due to recent financial performance and elevated risks.
The market appears to be pricing in a high level of fragility, with an expensive valuation compared to peers. There is a notable divergence driven by the company's optionality, but execution quality remains weak.
Fundamentals are expected to remain under pressure, with ongoing net losses and negative operating income reflecting the early-stage development phase. Management is focused on advancing preclinical projects, but the risk of an earnings miss is elevated.
The long-term thesis hinges on the performance of sector bellwethers like VRTX, REGN, and ARGX, which could influence TCRT's momentum. Additionally, successful advancement in preclinical development and formulation optimization will be crucial.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Nasdaq delisting or failure to satisfy listing rules
Address Nasdaq Listing Rule 5550(b)(1) compliance by maintaining minimum stockholders' equity to avoid delisting.
Newly stated in 2026-Q2 quarter. The company received a Nasdaq notice for failing to maintain the minimum $2.5M stockholders' equity required for listing. Financials show cash and equivalents of approximately $0.354M as of 2026-Q1, indicating a shortfall. The trajectory is concerning with regulatory compliance at risk.
“Received notice from Nasdaq for non-compliance with minimum stockholders' equity requirement.”
Breaks if: No strategic partnership engagement within next 4 quarters
Over the next 1 to 3 years, TCRT faces significant challenges, but its focus on R&D could yield results if market conditions improve. Not investment advice.